GLP-1 受体激动剂在 2 型糖尿病管理中的作用。
The role of GLP-1 receptor agonists in managing type 2 diabetes.
机构信息
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, OH.
Quality Improvement Officer, Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, OH; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
出版信息
Cleve Clin J Med. 2022 Aug 1;89(8):457-464. doi: 10.3949/ccjm.89a.21110.
Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control in patients with type 2 diabetes mellitus, have cardioprotective and renoprotective effects, and do not cause weight gain or significant hypoglycemia. In fact, they have been found to be effective for weight loss in patients with obesity with and without diabetes. They are now the preferred drugs to add to the regimen when oral metformin by itself is not enough to meet the patient's hemoglobin A1c goal.
胰高血糖素样肽-1（GLP-1）受体激动剂可改善 2 型糖尿病患者的血糖控制，具有心脏和肾脏保护作用，且不会导致体重增加或明显的低血糖。事实上，它们已被证明可有效减轻肥胖患者（无论是否患有糖尿病）的体重。当单独使用口服二甲双胍无法满足患者的糖化血红蛋白目标时，它们现在是添加到治疗方案中的首选药物。
Zotero 插件